Application No.: 08/937756 Docket No.: JJJ-P06-504

## **LISTING OF CLAIMS**

## 1-96. (**Canceled**)

- 97. (Previously presented) A method for decreasing neuronal cell death associated with a neuropathy, comprising contacting a neuronal cell at risk of such cell death with a morphogen comprising a dimeric protein, the dimeric protein having one or more of the following:
  - (1) a conserved C-terminal six-cysteine skeleton 60% identical to residues 43-139 of SEQ ID NO: 5;
  - (2) a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5;
  - (3) a conserved C-terminal six-cysteine skeleton 70% homologous to residues 43-139 of SEQ ID NO: 5; or
  - (4) an amino acid sequence of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vg1, Vgr-1, BMP3, BMP5, or BMP6; and

wherein the morphogen (i) stimulates the production of an N-CAM or L1 isoform in said neuronal cell, and (ii) decreases neuronal cell death associated with a neuropathy.

## 98. (Canceled)

- 99. (Previously presented) A method for decreasing neuronal cell death associated with a chemical or physical injury, comprising contacting a neuronal cell at risk of such cell death with a morphogen comprising a dimeric protein with:
  - (1) a conserved C-terminal six-cysteine skeleton 60% identical to residues 43-139 of SEQ ID NO: 5;
  - (2) a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5;

Application No.: 08/937756 Docket No.: JJJ-P06-504

(3) a conserved C-terminal six-cysteine skeleton 70% homologous to residues 43-139 of SEQ ID NO: 5; or

(4) an amino acid sequence of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vg1, Vgr-1, BMP3, BMP5, or BMP6; and

wherein the morphogen (i) stimulates the production of an N-CAM or L1 isoform in said neuronal cell, and (ii) decreases neuronal cell death associated with a chemical or physical injury.

## 100-104.(Canceled)

- 105. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is human OP-1.
- 106. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is mouse OP-1.
- 107. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, BMP2A, BMP2B, Vg1, Vgr-1, BMP5, or BMP6.
- 108. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, or BMP6.
- 109. (Previously presented) The method of claim 97 or 99, wherein the morphogen is a dimeric protein having a conserved C-terminal six-cysteine skeleton 60% identical to residues 43-139 of SEQ ID NO: 5.
- 110. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is a dimeric protein having a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5.
- 111. (Previously presented) The method of claim 97 or 99, wherein the morphogen is a dimeric protein having a conserved C-terminal six-cysteine skeleton 70% homologous to residues 43-139 of SEQ ID NO: 5.